Cohance Lifesciences Ltd Q2 FY27 Results Analysis: PAT Plunges 98%, Margin Guidance Unreachable

Cofacto Research Published November 06, 2026 5 min read

Negative

Cohance Lifesciences Ltd's Q2 FY27 numbers came in soft, with revenue of Rs. 476.65 Cr (-14.21% YoY) and PAT growth of -79.45% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details

Results date	November 06, 2026
Revenue (Q2)	Rs. 476.65 Cr (-14.21% YoY)
PAT (Q2)	Rs. 15.22 Cr (-79.45% YoY)
EBITDA margin	9.60% (-1360 bps YoY)
EPS (Q2)	Rs. 0.40 (-79.38% YoY)

Quarter Snapshot

Q2 FY27 delivered the guided sequential recovery (revenue +12.88% QoQ, adjusted EBITDA margin 2.2% to 9.6%), but YoY performance deteriorated sharply with revenue −14.21%, adjusted EBITDA −64.4%, and normalized owners' PAT of Rs.1.40 cr down ~98%, flattered by a Rs.13.82 cr one-off tax credit. Pharma CDMO (−27.4% YoY) and Specialty Chemicals (−40.6% YoY) drove the decline while Sapala nucleic acids (+33.6% YoY) and API+ (+6.2% YoY) grew. The FY27 margin guidance of ~21% appears unreachable, and the post-period TGPCB-ordered Suryapet closure adds an unquantified operational risk, though management's cited improved Q3/Q4 order book and restocking reloads offer a plausible H2 recovery path.

Q2 FY27 Expectations vs Results

Driver	Expected before results	What happened	Verdict
Sequential recovery vs trough	"in line with the guided sequential recovery"	Revenue +12.88% QoQ; adjusted margin 2.2%→9.6%	Played out
YoY behind on demanding base	"sequential improvement would still leave YoY comparisons behind"	Revenue −14.21% YoY	Played out
Gross-margin pressure flat-to-easing QoQ	"should not deepen on current spot"	70.8% vs 71.5% in Q1 (−70 bps QoQ; −377 bps YoY) — eased QoQ, still compressing YoY	Played out
NJ Bio drag persistent	"more likely persistent than reversed in Q2"	NCI loss widened YoY; H1 subsidiary drag −Rs.23.58 cr, Q2 gap narrowed	Played out
FX translation tailwind	"modest rupee appreciation… translation tailwind"	Other income −20.45% YoY; FX MTM gain Rs.3.6 cr in the adjusted bridge	Partially
No adverse tariff on generic flows in window	"no new tariff landed directly on COHANCE's generic flows"	Filing silent on tariffs	Not observable
Watch items: restocking quantification, quantified FY27 guidance, 483 CAPA outcomes, $1bn clarity, ADC payload delivery confirmation	all flagged as due on this call	None quantified/resolved in the filing (payload "progressing through scale-up") — remain open for the call	Not addressed in the filing

Read our full results preview.

Management Guidance vs Delivery

What management said	Where	What happened	Verdict
Sequential improvement in Q2 FY27 after the Q1 trough	Q1 FY27 earnings call (5 Aug 2026)	Revenue +12.88% QoQ; adjusted EBITDA margin 2.2% → 9.6%	Met
FY27 adjusted EBITDA margin "closer to previous year margin percentage" (FY26: 21.0%)	Q1 FY27 earnings call (CFO)	H1 FY27: 6.1%; see Section 9 — path	Missed
YoY revenue growth from H2 FY27	Q1 FY27 earnings call	H2 not yet reported; H1 −18.6% YoY	Too Early
FY27 capex ~INR 3,000 Mn	Q1 FY27 earnings call	Rs.1,077 Mn in H1 (36%)	On Track
Restocking quantification from the Rs.260 cr pool "by the end of the second call"	Q1 FY27 earnings call (CFO)	No quantification in the results materials	Too Early / open for the call
Quantified FY27 revenue-growth guidance	promised at successive calls since Q4 FY26	Still not provided	Too Early / open
US$1bn-by-2030 clarity by December 2026	Q1 FY27 earnings call (CEO)	Filing silent; "strategic direction remains unchanged"	Too Early
"Q2 delivered sequential growth" / adjusted EBITDA improving	Q2 press release	+12.88% QoQ revenue; adjusted margin 9.6% vs 2.2%	Confirmed
"Adjusted PAT also returned to positive territory"	Q2 press release	Adjusted PAT Rs.7.4 cr; reported owners' PAT Rs.15.22 cr (Rs.1.40 cr normalized)	Confirmed
"API+ revenue grew YoY, supported by selective pricing actions"	Q2 press release	API+ +6.2% YoY; API+ = 56% of Q2 revenue	Confirmed

Key Numbers, Quarter by Quarter

Metric	FY26	Q1 FY27	Q2 FY27	H1 FY27
Niche tech share	16.2%	15.1%	13.7%	14.4%
CDMO share	52%	38%	44%	41%
API+ YoY	—	—	+6.2%	—
Sapala YoY	—	—	+33.6%	+83.1%
Spec Chem YoY	—	—	−40.6%	—

Key Investment Insights

Key Positives

Revenue grew 12.88% QoQ to Rs.476.65 cr, meeting management's guided sequential recovery from the Q1 trough
Adjusted EBITDA margin recovered from 2.2% in Q1 to 9.6% in Q2 (adjusted EBITDA Rs.45.9 cr vs Rs.9.2 cr)
Nucleic acid business (Sapala) grew 33.6% YoY in Q2 and 83.1% in H1, with no Phase III supply contribution yet
API+ grew 6.2% YoY, the only business line to grow, supported by selective pricing actions
Two new commercial and one Phase III Pharma CDMO programme secured; management cites materially improved Q3/Q4 order book and reloads
Balance sheet remains net cash positive at Rs.56.05 cr (statement basis); H1 FCF of Rs.80.05 cr
Trade receivables fell 31.1% vs 31-Mar-26 to Rs.469.02 cr; NWC days improved to 148 from 154 in FY26

Risk Factors

Revenue declined 14.21% YoY in Q2 and 18.6% in H1 on lower Pharma CDMO (−27.4% YoY) and Specialty Chemicals (−40.6% YoY) contributions
Adjusted EBITDA fell 64.4% YoY to Rs.45.9 cr with margin at 9.6% vs 23.2%; normalized owners' PAT of Rs.1.40 cr is down ~98% YoY
Reported PAT of Rs.15.22 cr was positive only due to a Rs.13.82 cr earlier-years tax credit; standalone PBT was a loss of Rs.0.26 cr
Gross margin compressed 377 bps YoY to 70.8% on raw-material inflation and unfavourable mix; inventory build of Rs.97.55 cr signals production ahead of sales
NCI loss widened to Rs.12.95 cr YoY; H1 subsidiary contribution was −Rs.23.58 cr (NJ Bio/Aruka drag)
TGPCB ordered closure of the Suryapet facility on 5 November 2026 after a fatal industrial accident; impact unquantified; USFDA 483s at three sites unresolved
FY27 adjusted EBITDA margin guidance of ~21% is unreachable — H1 was 6.1% and the implied H2 margin would be ~37%